{"id":"W3007807247","doi":"10.1200/jco.2020.38.6_suppl.tps761","title":"Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Population Health Research Institute; Ontario Clinical Oncology Group; Health Sciences Centre; McMaster University Medical Centre; St. Joseph’s Healthcare Hamilton; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Kidney cancer; Renal cell carcinoma; Nivolumab; Contraindication; Internal medicine; Surgery; Sunitinib; Cancer; Oncology; Urology; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00174,0.001725412,0.001670057,0.0004824994,0.0003863137,0.0009682185,0.001280395,0.001530967,0.007222753],"category_scores_gemma":[0.0009018415,0.0006625209,0.001220414,0.0003527169,0.001097936,0.0008227571,0.0004332543,0.002938469,0.00134775],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001120861,"about_ca_system_score_gemma":0.001758244,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001252093,"about_ca_topic_score_gemma":0.002151766,"domain_scores_codex":[0.9996328,0.0001571577,0.00001392051,0.00008420295,0.000034055,0.00007779135],"domain_scores_gemma":[0.999357,0.000090029,0.0001316588,0.00005802125,0.00003235976,0.000330812],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9068463,0.03463491,0.001491778,0.0006623767,0.000814458,0.0001220474,0.000120824,0.001521798,0.01147485,0.0003403871,0.00295104,0.03901915],"study_design_scores_gemma":[0.8487864,0.1462558,0.00178899,0.00002154021,0.0001978892,0.00007931901,0.00001852895,0.0006037016,0.000922007,0.0001711016,0.001141978,0.00001281951],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823695,0.002305709,0.0009229606,0.000974679,0.0004480219,0.007094468,0.001658489,0.0002159922,0.004010105],"genre_scores_gemma":[0.9807498,0.001457389,0.002200755,0.0014088,0.0002676689,0.006456157,0.002861081,0.00003561884,0.004562769],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007222753,"threshold_uncertainty_score":0.02416247,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.183265086118783,"score_gpt":0.4824898356142194,"score_spread":0.2992247494954364,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}